|
|
||||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
REVIEW |
Rheumatic Diseases Unit, Western General Hospital, Edinburgh, UK
Correspondence to:
Correspondence to:
Dr E Suresh
Rheumatology Department, Kettering General Hospital, Rothwell Road, Kettering, Northants NN16 8UZ, UK; dr_esuresh{at}hotmail.com
ABSTRACT
Combinations of disease modifying antirheumatic drugs (DMARDs) are increasingly being used in patients with early rheumatoid arthritis (RA) when long term results with sequential DMARD monotherapy are disappointing. Combination DMARD therapy may be more effective than monotherapy, and has no additional short term adverse events. The evidence for using combination DMARD therapy is still weak, however, and further trials are needed.
Abbreviations: ACR, American College of Rheumatology; DMARD, disease modifying antirheumatic drug; RA, rheumatoid arthritis; TNF, tumour necrosis factor
Keywords: combination therapy; early rheumatoid arthritis
This article has been cited by other articles:
![]() |
Combination therapy for early rheumatoid arthritis DTB, November 1, 2006; 44(11): 81 - 85. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |